Bevacizumab biosimilar - Biocon/Mylan

Drug Profile

Bevacizumab biosimilar - Biocon/Mylan

Alternative Names: KRABEVA; MYL 1402O

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocon
  • Developer Biocon; Mylan
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Brain cancer; Cervical cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Renal cancer
  • Phase I Cancer

Most Recent Events

  • 23 Nov 2017 Launched for Brain cancer in India (IV)
  • 23 Nov 2017 Launched for Cervical cancer in India (IV)
  • 23 Nov 2017 Launched for Colorectal cancer (Late-stage disease) in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top